Novo Nordisk launches Wegovy weight-loss pill in Australia
Novo Nordisk said its oral Wegovy semaglutide treatment became available for private prescription in Australia from Friday, making it the first oral GLP-1 approved there for weight management. The product comes in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, with prices set at $260, $270, $280 and $395 respectively. Lilly’s competing Foundayo orforglipron has also received Australian approval and is expected to become available in the coming days.
Why it matters
The launch adds a tablet option to a market previously served by injectable GLP-1 treatments, while private-prescription status leaves patients responsible for the cost. Australian clinicians cited by the materials expect broader choice but raised concerns about affordability, inappropriate use and the limited evidence on long-term treatment risks.
Key facts
- 1Wegovy is available privately in Australia in strengths of 1.5 mg, 4 mg, 9 mg and 25 mg. www1.racgp.org.au
- 2The corresponding Wegovy prices are $260, $270, $280 and $395, respectively, before any pharmacy or service variation. www1.racgp.org.au
- 3Lilly’s Foundayo received Therapeutic Goods Administration approval and was expected to become available in the coming days. smh.com.au
- 4The two oral GLP-1 products were expected to cost between $250 and $395 per month depending on brand and dose. smh.com.au
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.